CAREFUSION Corp - FORM 8-K - EX-99.6

Attached files

file	filename
8-K - FORM 8-K - CAREFUSION Corp	d800587d8k.htm
EX-99.1 - EX-99.1 - CAREFUSION Corp	d800587dex991.htm
EX-2.1 - EX-2.1 - CAREFUSION Corp	d800587dex21.htm
EX-99.5 - EX-99.5 - CAREFUSION Corp	d800587dex995.htm
EX-99.7 - EX-99.7 - CAREFUSION Corp	d800587dex997.htm
EX-99.4 - EX-99.4 - CAREFUSION Corp	d800587dex994.htm
EX-99.3 - EX-99.3 - CAREFUSION Corp	d800587dex993.htm
EX-99.2 - EX-99.2 - CAREFUSION Corp	d800587dex992.htm

BD & CareFusion:

A new direction in healthcare

NAME

Title

Date

Exhibit 99.6

Aligned purpose

To touch the life

of every patient

around the world.

Helping all people

live healthy lives

~ $700 million

combined spend

~$12 billion combined

revenue

No. 5 largest

med-tech company

Unprecedented scale

Global Position

45,000+

>50,000 points of care,

120 countries

Revenue, R&D investment, customer and employee figures are annualized based on the total of BD and CareFusion

combined as of Oct. 1, 2014. Both companies will continue to operate separately and independently until their proposed

merger is complete, which is expected to happen by mid-2015. These figures are subject to change.

R&D Investment

Employees

Customers

Common focus

BD strategy:

Apply technology and

clinical knowledge

to make healthcare

more effective,

efficient

and safe

CareFusion vision:

To improve the safety

and cost

of healthcare

for generations to

come.

Complementary product portfolio

Dispensing

Technologies

Infusion

Systems

Respiratory

Technologies

Infection

Prevention

Surgical

/Interventional

Specialties

Respiratory

Disposables

Reduce Variation •

Improve Safety •

Improve Processes •

Reduce Waste

Medication Management

CareFusion

BD Medical

BD Diagnostics

BD Biosciences

Medication Management

Legal disclaimers

Forward Looking Statements

This communication contains certain estimates and other forward-looking statements (as defined under Federal securities laws). Forward looking statements generally are

accompanied by words such as “will”, "expect", "outlook" or other similar words, phrases or expressions. These forward-looking statements include statements regarding the

estimated or anticipated future results of BD, and of the combined company following BD’s proposed acquisition of CareFusion, the anticipated benefits of the proposed

combination, including estimated synergies, the expected timing of completion of the transaction and other statements that are not historical facts. These statements are

based on the current expectations of BD and CareFusion management and are not predictions of actual performance. These statements are subject to a number of risks and

uncertainties regarding BD and CareFusion’s respective businesses and the proposed acquisition, and actual results may differ materially. These risks and uncertainties include,

but are not limited to, the ability of the parties to successfully close the proposed acquisition, including the risk that the required regulatory approvals are not obtained, are

delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the transaction; risks relating to the

integration of CareFusion’s operations, products and employees into BD and the possibility that the anticipated synergies and other benefits of the proposed acquisition will not

be realized or will not be realized within the expected timeframe; the outcome of any legal proceedings related to the proposed merger; access to available financing for the

refinancing of BD’s or CareFusion’s debt on a timely basis and reasonable terms; the ability to market and sell CareFusion’s products in new markets, including the ability to

obtain necessary regulatory product registrations and clearances; the loss of key senior management or other associates; the anticipated demand for BD’s and CareFusion’s

products, including the risk of future reductions in government healthcare funding, changes in reimbursement rates or changes in healthcare practices that could result in lower

utilization rates or pricing pressures; the impact of competition in the medical device industry; the risks of fluctuations in interest or foreign currency exchange rates; product

liability claims; difficulties inherent in product development, including the timing or outcome of product development efforts, the ability to obtain regulatory approvals and

clearances and the timing and market success of product launches; risks relating to fluctuations in the cost and availability of raw materials and other sourced products and the

ability to maintain favorable supplier arrangements and relationships; successful compliance with governmental regulations applicable to BD, CareFusion and the combined

company; changes in regional, national or foreign economic conditions; uncertainties of litigation, as well as other factors discussed in BD’s and CareFusion’s respective filings

with the Securities Exchange Commission. BD and CareFusion do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof,

except as required by applicable laws or regulations.

Important Information for Investors

In connection with the proposed transaction, BD will file with the SEC a registration statement on Form S-4 that will constitute a prospectus of BD and include a proxy

statement of CareFusion. BD and CareFusion also plan to file other relevant documents with the SEC regarding the proposed transaction. INVESTORS ARE URGED TO READ THE

PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN

IMPORTANT INFORMATION. You may obtain a free copy of the proxy statement/prospectus (if and when it becomes available) and other relevant documents filed by BD and

CareFusion with the SEC at the SEC’s website at www.sec.gov. In addition, you will be able to obtain free copies of these documents by phone, e-mail or written request by

contacting the investor relations department of BD or CareFusion at the following: Monique N. Dolecki, Investor Relations – 201-847-5378 Monique_Dolecki@bd.com or Jim

Mazzola, Investor Relations – 858-617-1203 Jim.Mazzola@CareFusion.com.

Participants in the Solicitation

BD and CareFusion and their respective directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation

of proxies in respect of the proposed transaction. Information about BD’s directors and executive officers is available in BD’s proxy statement dated December 19, 2013 for its

2014 Annual Meeting of Shareholders and in subsequent SEC filings. Information about CareFusion's directors and executive officers is available in CareFusion's proxy

statement dated September 25, 2014, for its 2014 Annual Meeting of Stockholders. Other information regarding the participants in the proxy solicitation and a description of

their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC

regarding the merger when they become available. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or

investment decisions. You may obtain free copies of these documents from BD or CareFusion as indicated above. This communication shall not constitute an offer to sell or the

solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to

registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements

of Section 10 of the U.S. Securities Act of 1933, as amended.

Appendix

Infection

Prevention

Specialty

Disposables

Medical

Specialties

Procedural Solutions

CareFusion strategy

Infusion

Dispensing

Medical Systems

Improving the safety and cost of healthcare

Clinical Resources

Strategic Sales and International Commercial Operations

Global Customer Support

Enterprise Technology and Software

Shared Research and Development

Medication Management

Infusion Therapy

Vascular Access

Operating Room

Bedside Care

Respiratory

Infusion

Disposables

Skin prep

Surgical

Instruments

Interventional

Specialties

Ventilators

Diagnostics

Global Expansion

•

Customer Experience

•

Business Simplification

Anesthesia

Respiratory

•

Enabling safer, simpler and more effective

parenteral drug delivery

•

Improving clinical outcomes through new, accurate and

faster diagnostics;

•

Providing

tools and technologies to the research

community

that facilitate basic science, drug discovery

and cell therapy;

•

Enhancing disease management in diabetes,

women’s health and cancer, and infection control.

•

Improving clinical, laboratory and research practices

emerging markets

BD strategy and focus

BD’s Strategy is to Apply Technology and Clinical Knowledge

to Make Healthcare More Effective, Efficient and Safe.

The Five Areas of Focus Are:

BD Medical

Focuses on providing innovative solutions to reduce the spread of infection,

enhance diabetes treatment

and advance drug delivery.

Customers Served

•Hospitals and clinics

•Physicians’

office practices

•Consumers and retail pharmacies

•Governmental and nonprofit public health agencies

•Pharmaceutical companies

•Healthcare workers

Products

•Needles and syringes

•Intravenous catheters

•Safety-engineered and auto-disable devices

•Prefillable drug delivery systems

•Prefilled IV flush syringes

•Insulin syringes and pen needles

•Regional anesthesia needles and trays

•Sharps disposal containers

•Closed-system drug transfer devices

•BD Simplist™

line of ready-to-administer prefilled injectables

•Medication workflow solutions

BD SafetyGlide™

Injection Needle

BD Nexiva™

Closed IV

Catheter System

BD PosiFlush™

Heparin-filled Flush Syringe

BD Soluvia™

Prefillable

Microinjection System

Enabling safer, simpler and more effective

parenteral drug delivery

BD Emerald™

Syringe

BD Sterifill Advance™

Plastic Prefillable Syringe

BD Simplist™

line of

ready-to-administer

prefilled injectables

Attached files

Stock widget

Investing forum

CAREFUSION Corp Reports